#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liposarcoma Tuberous sclerosis complex Antiphospholipid syndrome Hodgkin's disease refractory Factor VIII deficiency Myxofibrosarcoma Encephalitis autoimmune Neovascular age-related macular degeneration Brain injury Stiff person syndrome Systemic scleroderma Haematological malignancy Cognitive disorder Congenital absence of bile ducts B-cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Medulloblastoma Langerhans cell sarcoma – Treatment Langerhans’ cell histiocytosis – Basic Information Small intestine leiomyosarcoma – Diagnostics Arterial tortuosity syndrome – Basic Information Paroxysmal nocturnal haemoglobinuria – Diagnostics Rosai-Dorfman syndrome – Life with Disease Myxofibrosarcoma – Basic Information Pituitary-dependent Cushing’s syndrome – Treatment Mantle cell lymphoma stage IV – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Olodaterol SEVUPARIN Tiotropium GXV813 Sulfasalazine Nizatidine Inclisiran Sodium Sabestomig Anthoxanthum Odoratum OLVEREMBATINIB Desvenlafaxine Benzoate Lorlatinib Tremelimumab Oric-114 Kyv-101 Molidustat Sodium HTL0022537 Levobupivacaine Hydrochloride Lacnotuzumab Rbd4059 More therapies…

    Learn about Your Condition

    Prodromal Alzheimer's disease Craniosynostosis Hyperthyroidism Follicular lymphoma stage IV Pharyngeal cancer stage II Transferrin decreased Eosinophilic oesophagitis Chronic myeloid leukaemia Spinal muscular atrophy Macular oedema Haemodialysis Hypertension Systemic mastocytosis Cirrhosis alcoholic Hyperchylomicronaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • A study of navenibart for long-term safety in patients with hereditary angioedema

    Recruiting

    3 1
    Investigated Drugs:
    • NAVENIBART
    Austria Bulgaria Czechia France Germany Hungary +5

  • A Study of PF-07868489 Safety and Effectiveness in Adults with Pulmonary Arterial Hypertension Who Participated in a Previous PF-07868489 Trial

    Recruiting

    2 1 1
    Investigated Drugs:
    • PF-07868489
    Belgium Czechia France Germany Greece Italy +1

  • Study of ONC206 for children and young adults with newly diagnosed or recurrent diffuse midline glioma and other recurrent brain tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Brain stem glioma
    • Ependymoma
    • Primitive neuroectodermal tumour
    The Netherlands

  • A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Denmark France Germany Italy The Netherlands Spain

  • A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Everolimus
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium France Germany Italy The Netherlands +2
Previous Page
1 … 76 77 78 79 80 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!